The abstract is read at the publisher; the summary is JClub's.
Surviving cancer cells under antimetabolite therapy are linked to a shared resistance program that recycles nucleotides and reshapes mitochondria, enabling continued growth.
- Why it matters: Antimetabolites have been used since the 1950s, but how tumors persist is unclear, limiting the ability to predict who will benefit from drugs that target nucleotide metabolism.
- What they did: Moss and colleagues and Witus and colleagues analyzed how resistant cells survive, focusing on nucleotide recycling and mitochondrial changes to define a measurable program.
- The result: Because this resistance program can be measured, it could help identify before treatment which patients would benefit from drugs that block the program.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.